KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Non Operating Income: 2009-2024

Historic Non Operating Income for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $844.4 million.

  • Regeneron Pharmaceuticals' Non Operating Income rose 130.92% to $755.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 43.73%. This contributed to the annual value of $844.4 million for FY2024, which is 274.96% up from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its Non Operating Income stood at $844.4 million for FY2024, which was up 274.96% from $225.2 million recorded in FY2023.
  • In the past 5 years, Regeneron Pharmaceuticals' Non Operating Income ranged from a high of $844.4 million in FY2024 and a low of $179.3 million during FY2022.
  • Its 3-year average for Non Operating Income is $416.3 million, with a median of $225.2 million in 2023.
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' Non Operating Income crashed by 58.90% in 2022, and later surged by 274.96% in 2024.
  • Yearly analysis of 5 years shows Regeneron Pharmaceuticals' Non Operating Income stood at $290.7 million in 2020, then surged by 50.09% to $436.3 million in 2021, then plummeted by 58.90% to $179.3 million in 2022, then climbed by 25.60% to $225.2 million in 2023, then spiked by 274.96% to $844.4 million in 2024.